Key Points
- Director Katherine Bach Kalin purchased 63,400 shares on Nov. 19 at an average price of $1.59 for a total of $100,806, increasing her ownership to 104,400 shares (a 154.63% increase) as disclosed in an SEC filing.
- SELLAS stock jumped 4.8% to $1.53 on Friday with ~2.94 million shares traded; the company has a market cap of about $218 million, a 12‑month range of $0.77–$2.48, and a negative PE of -4.78.
- SELLAS beat quarterly EPS estimates (reported ($0.06) vs. ($0.08) expected) and has a consensus analyst rating of Hold with a $7 price target, while institutional/hedge fund ownership stands around 17.38% and Weiss Ratings maintains a "sell (d-)".
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin purchased 63,400 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average cost of $1.59 per share, for a total transaction of $100,806.00. Following the acquisition, the director owned 104,400 shares of the company's stock, valued at approximately $165,996. The trade was a 154.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
SELLAS Life Sciences Group Stock Up 4.8%
SLS traded up $0.07 on Friday, hitting $1.53. 2,944,602 shares of the company traded hands, compared to its average volume of 2,806,831. SELLAS Life Sciences Group, Inc. has a 12-month low of $0.77 and a 12-month high of $2.48. The company has a 50 day moving average of $1.76 and a 200-day moving average of $1.76. The stock has a market capitalization of $217.94 million, a PE ratio of -4.78 and a beta of 2.64.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, research analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.
Hedge Funds Weigh In On SELLAS Life Sciences Group
Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in SELLAS Life Sciences Group by 21.9% in the third quarter. Bank of America Corp DE now owns 42,150 shares of the company's stock valued at $68,000 after purchasing an additional 7,571 shares during the last quarter. Anson Funds Management LP grew its holdings in SELLAS Life Sciences Group by 2,093.8% during the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company's stock valued at $9,713,000 after buying an additional 5,757,938 shares during the last quarter. Equitable Holdings Inc. increased its position in SELLAS Life Sciences Group by 58.6% during the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company's stock worth $44,000 after buying an additional 10,000 shares in the last quarter. Squarepoint Ops LLC raised its holdings in shares of SELLAS Life Sciences Group by 186.4% in the third quarter. Squarepoint Ops LLC now owns 46,180 shares of the company's stock worth $74,000 after acquiring an additional 30,058 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of SELLAS Life Sciences Group during the third quarter valued at $43,000. 17.38% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and a consensus price target of $7.00.
View Our Latest Stock Report on SLS
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
